Home › Atherosclerosis › Indiana
Atherosclerosis clinical trials in Indiana
6 studies for Atherosclerosis are looking for participants at sites in Indiana.
Cities in Indiana
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Franciscan Physician Network - Indiana Heart Physicians, Indianapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07783802A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Asha Clinical Research-Munster,Llc, Hammond
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07448038Pharmacogenomic Informed Statin Prescribing
- Richard L. Roudebush VA Medical Center, Indianapolis, IN, Indianapolis
Recruiting
Ages 40 to 75 · All sexes · Updated Nov 2, 2026 · NCT06568601Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- IU Health Bloomington, Bloomington
- Indiana University Health Methodist Hospital, Indianapolis
- Franciscan Physician Network - Indiana Heart Physicians, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07157774Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- NANI Research, Fort Wayne
- Nephrology Physician's LLC, Mishawaka
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Evansville
- Research Site, Evansville
- Research Site, Indianapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT07000357From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.